Novartis MS drug remibrutinib clears key Phase III

Unbranded MS drug capsules on a lab bench after positive Phase III trial results for remibrutinib

Key Points

01Remibrutinib met the primary endpoint in Phase III REMODEL-1 and REMODEL-2 in relapsing multiple sclerosis
02The drug significantly reduced annualized relapse rate versus teriflunomide
03Secondary endpoints showed fewer MRI brain lesions; a preplanned pooled analysis showed a clinically meaningful delay in disability progression (positive trend for 3‑month and nominal significance for 6‑month confirmed progression).
04Roughly 2,000 patients were enrolled, and safety was reported as favorable

Positive Phase III results in relapsing multiple sclerosis

Novartis (NVS) announced on September 1, 2026 that its oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib achieved positive topline results in two large Phase III studies, REMODEL-1 and REMODEL-2. Both trials were conducted in people with relapsing multiple sclerosis and were designed to compare remibrutinib with the oral therapy teriflunomide.

In each study, remibrutinib met the primary endpoint by significantly reducing the annualized relapse rate compared with teriflunomide. This primary outcome is a key measure of how frequently patients experience relapses of disease activity over time.

Approximately 2,000 patients with evidence of recent disease activity and an Expanded Disability Status Scale range of 0.0–5.5 were enrolled globally in the REMODEL program. Participants were randomized 1:1 to receive remibrutinib 100 mg or teriflunomide, providing a head-to-head comparison across a broad population of relapsing multiple sclerosis patients.

Superiority on key secondary endpoints

Beyond relapse reduction, remibrutinib demonstrated superiority versus teriflunomide on key secondary endpoints within each trial. These included a reduction in MRI brain lesions, an important marker of inflammatory disease activity in multiple sclerosis.

A preplanned combined analysis pooling data from REMODEL-1 and REMODEL-2 showed a clinically meaningful delay in disability progression for patients treated with remibrutinib. The analysis identified a positive trend in three-month confirmed disability progression and nominal statistical significance in six-month confirmed disability progression.

These findings suggest that remibrutinib’s effects extend beyond controlling relapses to influencing longer-term measures of neurological function. The consistency of results across primary and secondary endpoints reinforces the overall trial outcome.

Safety profile and next steps

Novartis (NVS) reported that remibrutinib demonstrated a favorable safety profile in the REMODEL trials. This safety assessment was based on the large, randomized patient population treated over the course of the studies.

The positive efficacy and safety results position remibrutinib as a potential new oral option in the treatment landscape for relapsing multiple sclerosis. Market commentary following the announcement highlighted strong commercial expectations and investor interest in the program.

More detailed data from REMODEL-1 and REMODEL-2 are planned for presentation in a fuller dataset in October. These data are expected to enable closer comparisons with other BTK inhibitors and established multiple sclerosis therapies as stakeholders assess remibrutinib’s role in future treatment strategies.

Key Takeaways

01Remibrutinib achieved statistically significant reductions in relapse rates versus an established oral comparator, supporting its potential as a competitive MS therapy.
02Signals of delayed disability progression, alongside MRI lesion reduction, indicate benefits that span both inflammatory activity and longer-term functional outcomes.
03The favorable safety profile in a roughly 2,000-patient program strengthens the clinical case for remibrutinib ahead of more detailed data disclosures.

References